<DOC>
	<DOCNO>NCT02277158</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose safety S-1 plus radiotherapy patient rectal cancer</brief_summary>
	<brief_title>Phase I Study CCRT Adjuvant Treatment Stage II/III Operable Rectal Cancer .</brief_title>
	<detailed_description>This stage I study design evaluate appropriate dose S-1 plus radiotherapy patient R0 resection rectal cancer stage II-III patient ( AJCC 7th ) . To evaluate safety , data adverse event collect time enrollment withdrawn complete whole study .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>R0 resection histologically prove stage II/III rectal cancer ; 1875 year old ; No previous radiotherapy chemotherapy rectal cancer ; Performance status ECOG 0,1 ; Adequate organ function define : i. WBC ≥ 4,000/mm^3 ii . ANC ≥ 1,500/mm^3 iii . Hemoglobin ≥ 10g/dL iv . Platelet ≥ 100,000/m^3 v. Total bilirubin ≤ 1.5ULN vi . AST/ALT ≤ 1.5ULN vii . Serum creatinine ≤ 1.5ULN creatinine clearance rate ≥ 60ml/min、Urea nitrogen ≤ 1.5ULN viii . Protein urine dipstick test＜1+ ; test result ＞1+ , total protein urea must ＜500mg within 24 hour Able receive oral administration Informed consent Hypersensitive S1 excipients Pulmonary fibrosis interstitial pneumonitis find within 28 day prior registration Significant comorbid medical condition , include , limited , heart failure , renal failure , hepatic failure , hemorrhagic peptic ulcer , mechanical paralytic ileus , poorly control diabetes Received investigational drug anticancer agent Pregnant lactate female pregnancy test positive Severe mental disorder Judged ineligible physician participation study due safety concern .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Rectal cancer</keyword>
	<keyword>S-1</keyword>
	<keyword>Chemoradiotherapy</keyword>
	<keyword>Phase I</keyword>
</DOC>